Is IPHA or KOD more undervalued in 2026?

CirclFi compares Innate Pharma S.A. (IPHA) and Kodiak Sciences Inc (KOD) using 13 institutional-grade valuation models. IPHA has a Quality of Company score of 4.8/10 while KOD scores 4.8/10.

Which is a better buy — IPHA or KOD?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do IPHA and KOD valuations compare?

IPHA at $1.83 and KOD at $36.71 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

IPHA vs KOD Valuation Comparison 2026 — Intrinsic Value Analysis

IPHA

Biological Products, (No Diagnostic Substances)

Innate Pharma S.A.

Quality

4.8

out of 10

Value Trap

LOW

Price

$1.83

Last close

Models

8/13

Active

KOD

Biological Products, (No Diagnostic Substances)

Kodiak Sciences Inc

Quality

4.8

out of 10

Value Trap

SAFE

Price

$36.71

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	IPHA Fair Value	IPHA Upside	KOD Fair Value	KOD Upside
Bayesian DCF	Intrinsic	$0.62	-66.1%	$11.85	-67.7%
Earnings Power Value	Intrinsic	—	—	$23.98	-46.5%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$0.87	-52.3%	$3.57	-90.3%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for IPHA vs KOD — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

IPHA vs KOD — Which Stock Is More Undervalued?

KOD scores higher with a 4.8/10 quality rating vs IPHA's 4.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Innate Pharma S.A. (IPHA) and Kodiak Sciences Inc (KOD) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

IPHA currently trades at $1.83 with a QOC of 4.8/10, while KOD trades at $36.71 with a QOC of 4.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).